Quantcast

Federal Pradaxa Lawsuits Move Forward, With Issuance of Order Pertaining to Discovery, Bernstein Liebhard LLP Reports

May 18, 2014

The Firm is investigating legal claims on behalf of alleged victims of Pradaxa bleeding side effects.

New York, New York (PRWEB) May 18, 2014

Thousands of Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) filed on behalf of patients who allegedly suffered life-threatening internal bleeding due to the drug continue to move forward in a multidistrict litigation underway in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to an Order issued on May 9, 2014, the Court has extended the defense deadline to complete production of discovery materials relating to Boehringer Ingelheim’s RE-LY clinical trial to May 22, 2014. As such, the Order also provides the Plaintiffs’ Steering Committee with additional time to review those materials, and has directed the Committee to advise the Court on or before May 29, 2014, of how much time its experts will need to supplement their reports(In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)

“Our Firm is pleased to see this proceeding moving forward, as we continue to hear from alleged victims of life-threatening Pradaxa bleeding side effects,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free and confidential case evaluations to patients who were allegedly harmed by Pradaxa.

Pradaxa Bleeding Allegations

Pradaxa is a blood-thinning drug approved to prevent strokes in people with atrial fibrillation. In February, 7 Action News in Detroit revealed that the U.S. Food & Drug Administration (FDA) has received reports of 12,494 injuries and 1,158 deaths among Pradaxa users since the blood thinner was launched in the U.S. in October 2010. Many of these cases detailed episodes of uncontrollable internal bleeding among Pradaxa patients.*

According to court documents, the RE-LY trial was an 18,000 patient study that was among the research submitted to the FDA to obtain approval of Pradaxa. Plaintiffs in more than 2,400 Pradaxa lawsuits pending in the Southern District of Illinois claim that Boehringer Ingelheim knew that the drug posed a deadly risk of internal bleeding at the time that it was cleared for sale, and wrongly touted Pradaxa as an improvement over decades-old warfarin. Among other things, the complaints note that there is no readily-available antidote for the internal bleeding that sometimes accompanies Pradaxa use, while warfarin bleeding can easily be stopped via the administration of vitamin K.

Individuals who were allegedly harmed by Pradaxa bleeding side effects may be entitled to compensation for medical bills, lost wages, pain and suffering, and other damages. To learn more about filing a Pradaxa lawsuit, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to schedule a free, no obligation case review.

*wxyz.com/money/consumer/pradaxa-lawsuit, 7 Action News, February 25, 2014

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info (at)consumerinjurylawyers(dot)com

http://www.pradaxalawsuithelp.com/

https://plus.google.com/115936073311125306742?rel=author

For the original version on PRWeb visit: http://www.prweb.com/releases/pradaxa-lawsuit/pradaxa-bleeding/prweb11862725.htm


Source: prweb



comments powered by Disqus